Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?

被引：0

作者：

Tavara, B. ^{[1
]}

Garrido, M. L. ^{[1
]}

Rodriguez, Z. ^{[1
]}

Rojas, M. ^{[1
]}

Lopez, L. ^{[1
]}

Medina, S. ^{[1
]}

Ponte, C. ^{[1
]}

Lopez, A. ^{[1
]}

Sanchez, E. ^{[1
]}

Pedraza, M. ^{[1
]}

Vinals, P. ^{[1
]}

Lopez, M. ^{[1
]}

Alonso, D. ^{[1
]}

Rodriguez, A. ^{[1
]}

Davila, E. ^{[1
]}

Castanon, C. ^{[1
]}

De Sande, L. M. ^{[1
]}

Nieto, B. ^{[1
]}

Vallejo Pascual, M. E. ^{[2
]}

Rodriguez, J. D. L. R. ^{[1
]}

Garcia Palomo, A. ^{[1
]}

Diz Tain, P. ^{[1
]}

机构：

[1] Complejo Asistencial Univ Leon, Leon, Spain

[2] Univ Leon, Leon, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期

关键词：

DURVALUMAB; PACIFIC; REAL WORLD DATA;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP05.02-0

引用

页码：S283 / S283

页数：1

共 50 条

[11] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Antonia, S. J.
Villegas, A.
Daniel, D.
Vicente, D.
Murakami, S.
Hui, R.
Yokoi, T.
Chiappori, A.
Lee, K. H.
de Wit, M.
Cho, B. C.
Bourhaba, M.
Quantin, X.
Tokito, T.
Mekhail, T.
Planchard, D.
Kim, Y. -C.
Karapetis, C. S.
Hiret, S.
Ostoros, G.
Kubota, K.
Gray, J. E.
Paz-Ares, L.
de Castro Carpeno, J.
Wadsworth, C.
Melillo, G.
Jiang, H.
Huang, Y.
Dennis, P. A.
Ozguroglu, M.
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1919 - 1929
[12] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Kim, Young-Hak
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 989 - 990
[13] Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study
Lim, Chloe Ahryung
Ghosh, Sunita
Morrison, Hali
Meyers, Daniel
Stukalin, Igor
Kerba, Marc
Hao, Desiree
Pabani, Aliyah
CURRENT ONCOLOGY, 2023, 30 (12) : 10396 - 10407
[14] Real-world outcomes with durvalumab (durva) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC (SPOTLIGHT)
Mooradian, M.
Allen, A.
Cai, L.
Xiao, Y.
Chander, P.
ANNALS OF ONCOLOGY, 2022, 33 : S86 - S86
[15] Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
Botticella, Angela
Mezquita, Laura
Le Pechoux, Cecile
Planchard, David
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
[16] Audit of chemoradiotherapy (CRT) in locally advanced non-small cell lung cancer
Wong, S. -L.
Morley, T.
Meng, K.
Mahmood, W.
Forster, M.
Mendes, R.
LUNG CANCER, 2015, 87 : S53 - S53
[17] Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)
Faehling, Martin
Schumann, Christian
Christopoulos, Petros
Hoffknecht, Petra
Alt, Juergen
Horn, Marlitt
Eisenmann, Stephan
Schlenska-Lange, Anke
Schuett, Philipp
Steger, Felix
Brueckl, Wolfgang M.
Christoph, Daniel C.
LUNG CANCER, 2020, 150 : 114 - 122
[18] Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab
Mouri, Atsuto
Watanabe, Satoshi
Tokito, Takaaki
Nagai, Yoshiaki
Saida, Yu
Imai, Hisao
Yamaguchi, Ou
Kobayashi, Kunihiko
Kaira, Kyoichi
Kagamu, Hiroshi
CANCERS, 2024, 16 (07)
[19] Who Benefits Most from Adjuvant Durvalumab after Chemoradiotherapy for Non-Small Cell Lung Cancer?
Ohri, N.
Halmos, B.
Bodner, W. R., III
Cheng, H.
Garg, M. K.
Gucalp, R.
Guha, C.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E85 - E86
[20] Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer Patients
Grass, G. Daniel
Naghavi, Arash O.
Abuodeh, Yazan A.
Perez, Bradford A.
Dilling, Thomas J.
CLINICAL LUNG CANCER, 2019, 20 (01) : E1 - E7

← 1 2 3 4 5 →